NCT01224795 - A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions

Influenza

Interventions

DRUG

Peramivir

Adults (≥ 18 years): Peramivir 600 mg, administered intravenously. Adolescents (12 to \< 18 years): Peramivir 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously.

DRUG

Placebo Comparator

Placebo Peramivir, administered intravenously.

Trial Locations (96)

Unknown

Birmingham

Hot Springs

Jonesboro

Little Rock

Mountain Home

Anaheim

Buena Park

Chino

Dinuba

Garden Grove

Lincoln

Los Angeles

Oceanside

Palm Springs

Port Hueneme

Sacramento

San Diego

Tustin

West Covina

Boulder

Centennial

Wheat Ridge

Milford

Brooksville

Coral Gables

Cutler Bay

Daytona Beach

Edgewater

Gainsville

Hialeah

Jacksonville

Miami

South Miami

West Palm Beach

Stockbridge

Boise

Aurora

Bloomingdale

Chicago

Peoria

South Bend

Dubuque

Arkansas City

Lenexa

Bardstown

Hazard

Paducah

Baton Rouge

Shreveport

Bangor

Hollywood

Rockville

Brockton

Fall River

Washington

Bozeman

Fremont

Lincoln

Omaha

Albuquerque

Camillus

Raleigh

Winston-Salem

Fargo

Akron

Dayton

Wadsworth

Owasso

Bend

Medford

Hatfield

Philadelphia

Scotland

Cranston

Cumberland

Johnston

Easley

Greenville

Bristol

Arlington

Austin

Beaumont

Bryan

Dallas

Forth Worth

Georgetown

Houston

Lake Jackson

North Richland Hills

San Antonio

Spring

Salt Lake City

South Jordan

West Jordan

Arlington

Charlottesville